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B-cell chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in the
Western world. It is a heterogeneous disease characterized by clonal proliferation and
the accumulation of CD5+ mature B lymphocytes. However, the normal counterpart from
which the latter cells arise has not yet been identified. CD27 expression and gene expres-
sion profiling data suggest that CLL cells are related to memory B-cells. In vitro, memory
B-cells differentiate into plasma cells when stimulated with CpG oligodeoxynucleotide
(CpG). The objective of the present study was therefore to investigate the ability of CpG,
in the context of CD40 ligation, to induce the differentiation of CLL B-cells into antibody-
secreting cells (ASCs). CD20+CD38− CLL B-cells were stimulated with a combination of
CpG, CD40 ligand and cytokines (CpG/CD40L/c) in a two-step, 7-day culture system. We
found that the CpG/CD40L/c culture system prompted CLL B-cells to differentiate into
CD19+CD20+CD27+CD38− ASCs. These cells secreted large amounts of IgM and had
the same shape as plasma cells. However, only IgMs secreted by ASCs that had differ-
entiated from unmutated CLL B-cells were poly/autoreactive. Class-switch recombination
(CSR) to IgG and IgA was detected in cells expressing the activation-induced cytidine deam-
inase gene (AICDA). Although these ASCs expressed high levels of the transcription factors
PRDM1 (BLIMP1), IRF4, and XBP1s, they did not downregulate expression of PAX5. Our
results suggest that CLL B-cells can differentiate into ASCs, undergo CSR and produce
poly/autoreactive antibodies. Furthermore, our findings may be relevant for (i) identifying
the normal counterpart of CLL B-cells and (ii) developing novel treatment strategies in CLL.
Keywords: chronic lymphocytic leukemia, CpG oligodeoxynucleotide, CD20, antibody-secreting cells, B-cell differ-
entiation, memory B cell, poly/autoreactive IgM
INTRODUCTION
B-cell chronic lymphocytic leukemia (CLL) is a heterogeneous dis-
ease characterized by clonal proliferation and the accumulation
of mature CD5+ B lymphocytes in the bone marrow, peripheral
blood, and lymphoid tissues (1). Although it has been suggested
that memory B-cells give rise to CLL B-cells (2, 3), the latter’s cel-
lular origin is still subject to debate. Nevertheless, identification of
the normal counterpart is crucial for clarifying the pathogenesis,
disease mechanism, and natural history of CLL. The observa-
tion that approximately half of all CLL patients carry somati-
cally mutated immunoglobulin heavy-chain variable (IgHV) genes
challenged the hypothesis in which CLL B-cells are derived from
CD5+ B-cells (because the latter rarely have IgHV mutations) (2).
It was then suggested that (i) mutated CLL B-cells were derived
from B-cells that had undergone a germinal center reaction (i.e.,
post-germinal-center antigen-experienced B-cells) and (ii) unmu-
tated CLL B-cells were derived from a pre-germinal center B-cells
(2). Gene expression profiling shows that only a relatively small set
of genes (20–100) can discriminate between mutated and unmu-
tated CLL clones (3, 4). Mutated and unmutated CLL B-cells
display a common, characteristic gene expression profile that is
largely independent of their IgV genotype and is more strongly
reminiscent of memory B-cells than of cells derived from naive
B-cells, CD5+ B-cells, or germinal center centroblasts/centrocytes
(3). Furthermore, the almost constant expression of CD27 seen
in CLL cells has been linked to a memory phenotype (2, 5).
Very recently, Seifert et al. performed transcriptome analyses of
CLL and normal B-cell subsets. The researchers controversially
reported that (i) unmutated CLL clones were derived from mature,
unmutated CD5+CD27− B-cells and (ii) mutated CLL clones were
derived from a distinct, previously unrecognized, CD5+CD27+
post-germinal-center (memory) B-cell subset (6). To address the
question of the CLL B-cells’ normal counterpart, most litera-
ture studies have used immunophenotypic, molecular, and gene
expressing profiling to look for similarities between CLL B-cells
and normal B-cells isolated ex vivo. Here, we propose a new way to
address the question of the normal counterpart: the comparison
of the phenotypic and functional features of antibody-secreting
cells (ASCs) generated from CLL B-cells or from normal B-cells.
Terminal B-cell differentiation is a multistage process dur-
ing which mature B-cells give rise to (i) short-lived ASC/plasma
cells in an extrafollicular response and (ii) long-lived ASC/plasma
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cells and memory B cells after a germinal center reaction (7).
Memory B-cells can survive for several months in the absence
of antigenic stimulation and provide an early antibody response
against recurrent infections (8, 9). In humans, between 30 and
40% of the B-cells in the peripheral blood are memory B-cells.
There are two main types of memory B-cells: (i) immunoglob-
ulin (Ig)-switched memory B-cells (CD27+IgD−IgG/A/E+) and
(ii) non-switched IgM+ memory B-cells, which include IgM-only
memory B-cells (CD27+IgM+IgD−) and a circulating subset of
marginal zone B-cells CD27+IgM+IgD+ called IgM memory B
cells, each of which accounts for about 15–20% of total B-cells
(9–12). Recent studies have shown that IgM memory B-cells
subset probably have a germinal center-independent origin; they
undergo somatic hypermutation (SHM) during generation of the
pre-immune repertoire and are solely involved in responses to T-
independent antigens (11–13). It is noteworthy that patients with
hyper-IgM syndrome type I [resulting from defects in the gene for
CD40 ligand (CD40L)] have IgM memory B-cells (with SHMs)
but not switched memory B cells (11, 12, 14). These patients
are unable to generate germinal centers and have low or null
serum IgG, IgA, and IgE levels and normal or elevated serum IgM
levels (11, 12).
The Toll-like receptor (TLR) 9 is activated by CpG
oligodeoxynucleotide (CpG) motifs present in unmethylated viral
and bacterial DNA (15). In humans, the CpG ligand has a key
role in the maintenance of memory B-cells and the establish-
ment of long-term serological memory and natural antibody
production (8, 15). In vitro, human memory B-cells differen-
tiate into ASCs in response to polyclonal stimuli, bystander T
cell help (CD40L) and CpG oligodeoxynucleotide (8, 15–21).
In fact, TLR9 (22, 23), CD40L–CD40 interactions (24, 25), and
cytokines (26) are all important components of the CLL microen-
vironment. In vitro, CD40 stimulation of CLL B-cells results in
NF-κB activation and is used as a model to mimic the lymph
node microenvironment (25, 27). As with normal B-cells, CLL
B-cells express a functional TLR9 (22, 23). Stimulation through
the TLR9 activates CLL B-cells and induces an immunogenic
phenotype (22, 23). It was recently suggested that studying TLR9
responses could provide further insight in the physiopathology
of CLL and thus lead to the development of novel therapeutic
strategies (28). Gutierrez et al. have shown that CpG induces CLL
B-cells to differentiate into ASCs (29). However, these authors were
not working with isolated CLL B-cells. Furthermore, they used a
one-step culture system and did not characterize the immunophe-
notypic and molecular features of the generated ASCs. In the
present study, we stimulated purified CLL B-cells with a com-
bination of CpG, CD40L and cytokines (referred to hereafter as
the “CpG/CD40L/c” condition) and investigated their ability to
differentiate into ASCs/plasma cells in a 7-day, two-step culture
model. We also characterized the cytomorphologic, immunophe-
notypic, molecular, and functional features of the resulting ASCs.
Lastly, in order to functionally define a normal cellular coun-
terpart for CLL B-cells, we tried to establish a link between
the functional characteristic of ASCs generated from CLL B-
cells and those generated from normal B-cell subpopulations (as




Chronic lymphocytic leukemia B-cells were obtained from the
peripheral blood of 12 treatment-naive patients [three women and
nine men; median (range) age: 67 (48–82)] diagnosed according
to the international guidelines (Table 1). All patients displayed the
clonal expansion of small, CD38-negative lymphocytes with high
nucleus/cytoplasm ratios and co-expression of CD19, CD5, and
CD23. In six of the 12 patients (# 3, 4, 6, 9, 10, and 12), muta-
tional status of the IgHV genes was determined: three patients had
unmutated IgHV genes (i.e., <2% mutations at the DNA level)
and three patients had mutated IgHV genes (i.e.,>2% mutations)
(Table 1). Normal B-cells were isolated from the peripheral blood
of healthy volunteers. All 12 patients and two healthy subjects
provided their written informed consent to participation in the
study. All procedures involving patient samples were approved by
Table 1 | Patient characteristics and VDJH rearrangements.
Patient Sex Age Binet stage Matutes score CD38 Cytogenetics Mutational status VH DH – JH
1 M 65 A 5 – 13q14 del ND ND ND
2 M 80 A 5 – ND ND ND ND
3 F 59 B 5 – 13q14 del M (10.7%) VH4–34 DH3–22 – JH4
4 M 65 A 5 – Trisomy 12 UM VH1–69 DH3–3 – JH3
5 F 80 A 5 – ND ND ND ND
6 M 82 A 5 – NORMAL M (8.3%) VH3–33 DH4–17 – JH4
7 M 55 A 5 – 13q14 del ND ND ND
8 M 76 A 5 – Trisomy 12 Monosomy 9 ND ND ND
9 M 75 A 4 – ND UM VH1–69 DH3–10 – JH5
10 M 48 B 5 – 13q14, 11q del UM VH3–49 DH3–3 – JH4
11 M 69 A 5 – 17p del ND ND ND
12 F 68 A 4 – ND M (10.6%) VH4–34 DH5–24 – JH4
del: deletion; ND: not determined; M: mutated; UN: unmutated; VH DH and JH: heavy-chain variable, diversity, and joining region gene segments, respectively.
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the local investigational review board (Comité de Protection des
Personnes Nord-Ouest, Amiens, France).
CELL ISOLATION AND CULTURE
Peripheral blood mononuclear cells were isolated by Ficoll density
gradient centrifugation of heparinized venous blood samples from
CLL patients. CD19+CD5+ CLL B-cells were purified by nega-
tive selection using magnetic bead-activated cell sorting (MACS),
with a B-cell (B-CLL) isolation kit (Miltenyi Biotec). The purity
of all preparations was around 98% and the cells co-expressed
CD19 and CD5 at their surface (as assessed by flow cytometry).
Direct labeling with anti-CD2, CD14, and CD56 antibodies was
always used to check that purified CLL B-cells were not contam-
inated by other immune cells. Cells were cultured in RPMI 1640
medium (Gibco-Invitrogen) [supplemented with 10% fetal calf
serum (PAA), 100 IU/ml penicillin, 100µg/ml streptomycin, and
2 mM l-glutamine] at 37°C in a 5% CO2 humidified incubator.
On day 0 (D0), purified CLL B-cells were seeded at a concen-
tration of 2× 106/ml and stimulated for 4 days with phosphoroth-
ioate CpG oligodeoxynucleotide 2006 (10µg/ml; Sigma-Aldrich)
in association with histidine-tagged soluble recombinant human
CD40L (50 ng/ml) and anti-polyhistidine monoclonal antibody
(mAb) (5µg/ml; R&D Systems) and a combination of inter-
leukin (IL)-2 (50 ng/ml), IL-10 (50 ng/ml), and IL-15 (10 ng/ml).
The cells were cultured in 5 ml in six-well, flat-bottomed culture
plates.
On D4, the cells were harvested,washed,and seeded at a concen-
tration of 106/ml and cultured in the presence of IL-2 (50 ng/ml),
IL-6 (50 ng/ml), IL-10 (50 ng/ml), and IL-15 (10 ng/ml) for 3 days.
On D7, cells were harvested, washed, and analyzed. All human
recombinant cytokines were purchased from PeproTech EC.
Normal B-cells were cultured as described previously (17).
IMMUNOPHENOTYPIC ANALYSIS
Cells were stained with appropriate combinations of fluorochrome-
conjugated antibodies in direct immunofluorescence assays. The
suppliers and specificities of the applied mAbs and the murine
isotype-matched controls are given in Table S1 Supplementary
Material. The Cytofix/Cytoperm kit (BD Biosciences) was used
for intracellular staining of IgM, IgG, and CD38, according to
the manufacturer’s instructions. Flow cytometry analysis was per-
formed with a FACSCantoII flow cytometer (BD Biosciences).
FlowJo software (Tree Star) was used for data analysis. Antigen
density was expressed as the relative fluorescence intensity (RFI),
i.e., the ratio between the mean fluorescence intensity (MFI) of
cells labeled with a specific antibody and the MFI of cells labeled
with a matched isotype control.
MORPHOLOGICAL ANALYSIS
For the morphological analysis on D7, cells were cytospinned
(500 rpm, 5 min). Cytospin smears were stained with May-
Grünwald–Giemsa (MGG) reagent and viewed under a light
microscope (Axio Imager. M2; Zeiss) equipped with an Axio-
Cam MRc5 microscope digital camera. Images were acquired using
ZEN pro Software (Zeiss). We used PowerPoint software to render
images with uniform backgrounds.
QUANTITATIVE REAL-TIME PCR ANALYSIS
On D0 and D7, total RNA was isolated from cells using
an RNeasy Mini kit (Qiagen). One microgram of total RNA
was used for cDNA synthesis with a High Capacity cDNA
Archive kit (Applied Biosystems). For transcript detection with
quantitative real-time PCR (qRT-PCR), primers, probes, and
TaqMan® Universal PCR Master Mix were used according to
the manufacturer’s instructions (Applied Biosystems) and PCRs
were run on a StepOnePlusTM Real-time PCR system (Applied
Biosystems). The TaqMan® Gene Expression Assays for PRDM1
(BLIMP1) (Assay ID Hs00153357_m1), PAX5 (Hs00172003_m1),
EBF1 (Hs00395524_m1), BCL6 (Hs00277037_m1), XBP1s (Hs
03929085_g1), IRF4 (Hs01056533_m1), IRF8 (Hs01128710_m1),
BACH2 (Hs00222364_m1), GAS6 (Hs01090305_m1), AICDA
(Hs00757808_m1), IGHA1 (Hs00733892_m1), IGHG1 (Hs00378
340_m1), CD38 (Hs01120071_m1), and CD138 (Hs00896423_
m1) were purchased from Applied Biosystems. For quantitation,
β2-microglobulin (B2M, 4333766F) was used as an endogenous
control. Variations in mRNA expression were calculated using the
2−∆∆CT qRT-PCR method, where∆∆CT=∆CT D7−∆CT D0.
For growth-arrest-specific gene 6 (GAS6), AICDA, IGHG1, and
IGHA1 the change in mRNA expression was determined using the
2–∆CT method, where ∆CT=CT of target gene – CT of B2M.
ANALYSIS OF IgM, IgG, AND IgA SECRETION
The levels of human IgM, IgG, and IgA in the culture supernatants
were quantified with the appropriate ELISA kit (Bethyl Laborato-
ries). Immunoglobulin production (in micrograms per 106 cells)
was estimated by dividing the total amount of Ig in the culture
supernatant by the number of live cells.
INDIRECT IMMUNOFLUORESCENCE ASSAYS
Slides coated with HEp-2 cells (INOVA Diagnostics) were incu-
bated with culture supernatant for 1 h at room temperature,
washed in PBS, incubated with an FITC-conjugated anti-human
IgM antibody and viewed under a fluorescence microscope (Axio
Imager M2; Zeiss) equipped with an AxioCam MRc5 micro-
scope digital camera. Images were acquired with ZEN pro soft-
ware (Zeiss). Positive controls (serum samples from patients
with the autoimmune disease scleroderma) and negative con-
trols (culture medium) were included in all experiments. The
term poly/autoreactivity was used to indicate (i) autoreactivity
(when staining was positive) and (ii) polyreactivity (when several
cell components stained positive – the nucleus and cytoplasm, for
example).
CLONALITY ASSESSMENT, V(D)J SEQUENCING, AND SOMATIC
HYPERMUTATIONS ANALYSIS
For CLL samples (# 3, 4, 6, 9, 10, and 12), genomic DNA was
extracted using the QIAamp spin column technology (Qiagen).
Immunoglobulin heavy-chain (IgH) and immunoglobulin light
chain (IgL) gene rearrangements were analyzed in a multiplex
PCR using the standardized BIOMED-2 PCR protocol (30). The
PCR products were electrophoretically separated on a 3500xL
Dx Genetic Analyzer (Applied Biosystems) and size analysis was
performed using GeneMapper® Software v4.1. For the size analy-
sis, 1µl of PCR product was mixed with 0.5µl of a dye-labeled
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size standard (GeneScan™ 500 LIZ™ dye Size Standard, Applied
Biosystems) and 12µl of deionized formamide (Hi-Di™ For-
mamide, Life Technologies). The mixture was heated at 95°C
for 1 min prior to microcapillary electrophoresis. Monoclonality
was defined as one or two peaks of amplified PCR products in
a GeneScan analysis. For the analysis of V (D), and J sequences,
approximately 50 ng of the purified PCR product were sequenced
using a BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems), according to the manufacturer’s instructions. Elec-
tropherograms were analyzed with Sequencing Analysis v.5.4
software (Applied Biosystems) and sequence data were analyzed
using the international ImMunoGeneTics information system®
(IMGT®, http://www.imgt.org) (31) and the Basic Local Align-
ment Search Tool (BLAST) database. The mutation rate in the
rearranged IgVH gene was defined as the percentage of mutations
per VH sequence, after sequencing and detection of mutations in
both the sense and antisense strands (Table 1).
STATISTICAL ANALYSIS
All statistical analyses were performed with Prism 5 software
(GraphPad Software). The statistical significance of intergroup
differences was determined using the Wilcoxon test or Stu-
dent’s t -test, as appropriate; p values below 0.05 were con-
sidered to be statistically significant and p values below 0.01
were considered to be highly statistically significant. Significant
differences are denoted as follows: *p< 0.05, **p< 0.01, and
***p< 0.001.
RESULTS
CLL B-CELLS AND NORMAL B-CELLS RESPOND DIFFERENTLY IN THE
CpG/CD40L/C CULTURE SYSTEM
To validate the effectiveness of the CpG culture system, we used
normal B-cells from healthy donors as a positive control [as
described in Ref. (17)]. As shown in Figure 1A, the expression
of CD38 (a marker of B-cell activation and plasma cell differenti-
ation) was increasingly expressed on the surface of normal B-cells
at each step in the CpG/CD40L/c culture system (it increases
from 18± 4.2% at D0 to 70± 8% at D7). On D7, the appear-
ance of a population of CD20low/−CD38high cells (it increases
from 1.2± 0.5% at D0 to 40± 2.8% at D7) confirmed that the
CpG/CD40L/c culture system was working properly (Figure 1A).
When compared with normal B-cells, CLL B-cells differed in
their response under the same culture conditions (Figure 1B).
On D0, the cells were CD20+CD38−. On D7, we first noted the
absence of marked surface CD38 expression in CpG/CD40L/c-
stimulated cells (Figures 1A,B). In order to establish whether
CD38 was expressed but not directed to the cell surface, we checked
for cytoplasmic CD38 and CD38 mRNA expression. As shown in
Figures 1C,D, CD38 expression was absent in the cytoplasm and
mRNA levels were only slightly upregulated on D7.
In order to investigate possible changes in the immunophe-
notype on D7, cells were stained for CD19, CD20, CD27,
CD45, CD25, CD138, and HLADR (Figure 2A). CpG/CD40L/c-
stimulated cells significantly upregulated their expression of CD20
and CD19 on D7, whereas CD27 and CD45 expression did not
change significantly. On D7, the cells also significantly upregu-
lated their expression of HLADR and CD25 (Figure 2A). Although
cell surface CD138 expression was not detected (data not shown),
CD138 mRNA levels were significantly upregulated (Figure 2B).
DAY-7-GENERATED CELLS DEVELOP AN ASC/PLASMA CELL
MORPHOLOGY
As shown by MGG staining (Figure 3A), D0 CLL B-cells presented
a normal-shaped nucleus that was surrounded by a thin ring of
cytoplasm. On D7, CpG/CD40L/c-stimulated cells showed a typ-
ical ASC/plasma cell morphology, i.e., an eccentric nucleus and
abundant cytoplasm. Consistent changes in cell morphology were
also monitored by flow cytometry, on the basis of the cells’ relative
size (forward scatter, FSC) and granulometry (side scatter, SSC)
(Figure 3B).
DAY-7-GENERATED CELLS EXPRESS SIMULTANEOUSLY PLASMA CELL
AND B-CELL TRANSCRIPTION FACTORS
To further understand phenotypic changes in D7-generated cells,
we studied the mRNA expression of several transcription factors
that are found in B-cells [PAX5, BCL6, BACH2, IRF8, and early
B-cell factor 1 (EBF1)] and are known to be involved in plasma
cell differentiation [IRF4, PRDM1, and X-box binding protein
1 spliced form (XBP1s)] (Figure 4). On D7, we observed that
CpG/CD40L/c-stimulated cells displayed a significant increase in
transcription of the IRF4, PRDM1, XBP1s genes and a signifi-
cant decrease in the transcription of the BACH2 and IRF8 genes
(Figure 4A). However, mRNA expression of PAX5 and BCL6
was not affected (Figure 4A). Moreover, mRNA expression of
growth-arrest-specific gene 6 (GAS6) (Figure 4B) and EBF1 was
significantly induced on D7 (Figure 4C).
MUTATED AND UNMUTATED CLL B-CELLS DIFFERENTIATE INTO
IgM-SECRETING CELLS
To establish whether the stimulation conditions induced CLL
B-cells to differentiate into ASCs, we assessed the cytoplasmic
expression and secretion of Igs in three mutated CLL samples
and three unmutated CLL samples. On D0, IgM was absent from
the surface, or present in only small amounts (Figure 5A). On D7,
IgM expression on the cell surface was significantly upregulated
(Figure 5A). On D0, all the CLL B-cells expressed cytoplasmic
IgM. On D7, cytoplasmic expression of IgM was upregulated
(Figure 5A). We then used ELISAs to investigate IgM, IgG, and IgA
secretion into the culture supernatant on D4 and D7 (Figure 5B).
When compared with cell culture in the absence of stimulation
(i.e., in medium only), CpG/CD40L/c-stimulated mutated and
unmutated CLL B-cells secreted significant amounts of IgM. Con-
siderable amounts of secreted IgM could be detected as early as D4
(Figure 5B). Moreover, the presence of at least moderate levels of
IgG and IgA revealed that class-switch recombination (CSR) was
triggered in two of the three unmutated CLL samples (and none of
the mutated samples) (Figure 5C). Expression of AICDA mRNA
was detected in cells in which CSR was observed (Figure 5D).
Furthermore, gamma and alpha H-chain transcripts were upreg-
ulated in the two CLL samples with CSR (Figure 5E). To check
whether or not the IgA and IgG were being secreted by contam-
inating, residual, normal B cells, we used PCR DNA sequencing
and high-resolution PCR fragment analysis (GeneScan) to study
Ig light and heavy-chain gene rearrangements and monoclonality.
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FIGURE 1 | CD20 and CD38 expression on normal and CLL B-cells. Cells
were stimulated with CpG, CD40L, and the cytokines IL-2, IL-10, and IL-15. On
day 4 (D4), cells were harvested and incubated with IL-2, IL-6, IL-10, and IL-15
for 3 days. (A,B) Cells were labeled with anti-CD20 and anti-CD38 mAbs to
examine changes in surface expression on normal B-cells (A) and CLL B-cells
(B) on D0, D4, and D7. Cytometry plots are representative of two and nine
independent experiments for normal B-cells and CLL B-cells, respectively.
(C) Cells were labeled with anti-CD38 after permeabilization. Cytometry plots
of cytoplasmic CD38 are representative of four experiments. (D) Expression
of the CD38 gene was evaluated using qRT-PCR in D0 CLL B-cells and
D7-stimulated cells. The results are expressed relative to the gene expression
in CLL B-cells on D0, according to the 2−∆∆CT method. Bars represent
mean±SEM values from five experiments. Statistical significance was
calculated in a Wilcoxon test. ns, not significant. D, Day. Cy, Cytoplasmic.
The fragment analysis showed that cells were always clonal after
differentiation on D7 (Figure 6). Sequencing of the CDR3 regions
showed that the sequences were identical at D0 and D7 (data not
shown).
IgMS SECRETED BY ASCS DERIVED FROM UNMUTATED CLL B-CELLS
ARE POLY/AUTOREACTIVE
To determine whether the secreted IgM antibodies were
poly/autoreactive, we performed indirect immunofluorescence
assays on slides coated with HEp-2 cells (Figure 7). We found
that the IgMs secreted by ASCs derived from unmutated CLL
B-cells displayed a cytoplasmic or nuclear/cytoplasmic staining
pattern (Figure 7). In contrast, IgMs secreted by ASCs derived
from mutated CLL B-cells were not poly/autoreactive (Figure 7).
DISCUSSION
In the present study, we looked at whether CpG stimulation in the
context of CD40 ligation was able to induce CLL B-cells to differ-
entiate into ASCs/plasma cells in a 7-day, two-step culture system.
Differentiation into ASCs/plasma cells involves profound phe-
notypic, molecular and morphologic changes, as mature B-cells
are transformed into cells capable of producing large amounts of
antibodies (7). Classically, B-cell differentiation leads to the down-
regulation of B-cell surface markers (such as CD19 and CD20),
the expression of plasma cell markers (such as CD38 and CD138),
and a switch from surface-displayed Igs to cytoplasmic/secreted
Igs. These phenotypic changes correlate with decreased expres-
sion of B-cell transcription factors (such as PAX5, BCL6, IRF8,
and BACH2), the expression of plasma cell transcription factors
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FIGURE 2 |The immunophenotype of the generated cells on D7. On D0
and D7, the cell immunophenotype was studied by direct labeling of CD19,
CD20, CD27, CD45, CD25, and HLADR. (A) Relative fluorescence
intensities (RFIs) were calculated as the ratio between the mean
fluorescence intensity (MFI) of cells labeled with a specific antibody and
the MFI of cells labeled with a matched isotype control. Mean±SEM RFI
values from nine experiments are represented with a color code: black: D0
values, blue: D7 CpG/CD40L/-stimulated cells. Cytometry data are
presented as plots from a representative patient. (B) The expression of the
(Continued)
FIGURE 2 | Continued
CD138 gene was evaluated with qRT-PCR in D0 CLL B-cells and
D7-stimulated cells. Results are expressed relative to gene expression in
CLL B-cells on D0, according to the 2−∆∆CT method. Bars represent the
mean±SEM values from five experiments. Statistical significance was
calculated in a Wilcoxon test. *The D7 value differs from the D0 value in CLL
B-cells. *p<0.05, **p<0.01, and ***p<0.001. ns, not significant. D, Day.
(such as IRF4, BLIMP1, and XBP1) and the acquisition of a plasma
cell morphology (e.g., an eccentric nucleus and the abundant
cytoplasm required for antibody secretion) (7).
Our data show that when stimulated with CpG/CD40L/c,
CLL B-cells differentiated into CD20+CD27+CD38−ASCs, which
were able to produce large amounts of IgM. Importantly, we evi-
denced significant upregulation of mRNA levels for the plasma
cell marker CD138. However, human ASCs/plasma cells have a
heterogeneous phenotype (32, 33) that is related to their exact
anatomic site and their degree of maturation; indeed, human ton-
sillar plasma cells were shown to express CD20 but not the plasma
cell marker CD138 (32, 34, 35). Moreover, CD20+ human tonsillar
plasma cells were shown to express both BLIMP1 and PAX5 (32).
However, it was suggested that the differential expression of human
CD38, CD138, HLADR, and CD20 may correspond to alternative
or additional ASC subsets derived from independent differentia-
tion pathways in blood, bone marrow, and possibly other tissues
(33). Hence, the molecular and immunophenotypic signature of
these ASCs may reflect a transitional stage during plasma cell dif-
ferentiation. Nevertheless, the cells’ phenotype can be explained by
the modulation of transcription factor expression. We noted the
induction of mRNA expression of the early B-cell factor 1 (EBF1)
transcription factor, which is known to regulate the expression of
the PAX5 gene (36). In our experiments, PAX5 expression was
slightly upregulated in CpG/CD40L/c-stimulated cells. Indeed,
PAX5 and EBF1 have been shown to induce and regulate the
expression of CD19 and CD20 in B-cells (36, 37). Moreover,
expression levels of the BCL6 gene (encoding a transcription factor
required for germinal center formation and the maintenance of a
centroblast phenotype (38)) did not change during the cell culture.
Data from our qRT-PCR experiments also revealed the upregula-
tion of plasma cell transcription factors PRDM1 (BLIMP1), IRF4,
and XBP1s (7, 38) and downregulation of B-cell transcription fac-
tors BACH2 and IRF8 (39). BACH2 is a PRDM1 inhibitor and
so BACH2 downregulation enhances BLIMP1 expression (39).
Furthermore, it is known that IRF4 induces BLIMP1 and XBP1
expression, indeed, BLIMP1 is required for plasma cell formation
and the subsequent production of high levels of Ig (7, 40). X-
box binding protein 1 (XBP1) is a transcription factor involved
in plasma cell differentiation. It has a role in the unfolded pro-
tein response (UPR) that is essential for the secretion of large
amounts of Ig by plasma cells (41). Only the spliced form of XBP1
(XBP1s) can activate the UPR efficiently (42). In our experiments,
cells showed significant induction of GAS6 mRNA on D7. GAS6
is a member of the vitamin K-dependent protein family. Gene
expression profiling data has shown that GAS6 is more strongly
expressed in plasmablasts and plasma cells than in mature B-
cells (43). GAS6 mRNA is present at negligible levels in precursor
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FIGURE 3 | Morphological analysis of D0 CLL B-cells and D7-stimulated
cells, as revealed by MGG staining and flow cytometry. (A) CLL B-cells
(D0) and stimulated cells (D7) were stained with MGG reagent. Original
magnification: ×1000. (B) Cell size and granularity were measured by flow
cytometry. The relative cell size is determined by light diffracted at small
angles [detected as forward scatter (FSC)]. The granularity is proportional to
the light diffracted at large angles [detected as side scatter (SSC)]. The
statistical significance was calculated in a Wilcoxon test: **p< 0.01.
B-cells and B-cell lines but is detected in terminally differenti-
ated plasma cell lines (44). Taken as a whole, our data show that
CpG/CD40L/c activation induces CLL B-cells to differentiate into
CD20+ IgM-secreting cells with an alternative immunophenotype
and molecular profile.
CpG/CD40L/c stimulation clearly triggered CSR because at
least moderate levels of IgG and IgA were detected in two of the six
CLL samples. Interestingly, CSR was observed in two of the three
unmutated CLL B-cell samples but not in any of the three mutated
CLL B-cell samples. The presence of CSR was also confirmed by
the upregulated expression of AICDA mRNA and gamma and
alpha H-chain transcripts. Indeed, CLL B-cells were shown to
undergo CSR in vivo (45). Similar results have been obtained
in vitro by other researchers (46). Importantly, unmutated CLL
B-cells were shown to express activation-induced cytidine deam-
inase and undergo CSR but not SHM (47, 48). SHM occurs in
the variable region of the Ig heavy-chain and allows production
of high-affinity, less autoreactive antibodies. Importantly, a great
number of unmutated CLL B-cells express poly/autoreactive anti-
bodies (49–51). In agreement with a previous study (49), our data
show that only IgMs secreted by ASCs derived from unmutated
CLL B-cells are poly/autoreactive.
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FIGURE 4 | Day 7 mRNA expression analysis of transcription
factors involved in B-cell-to-plasma-cell differentiation. (A,C) The
transcriptional expression of BCL6, PAX5, BACH2, IRF8, IRF4, PRDM1,
XBP1s, and EBF1 genes was evaluated in a qRT-PCR on D0 and D7. The
results are expressed relative to gene expression in CLL B-cells on D0,
according to the 2−∆∆CT method. Data are expressed as the
mean±SEM from five experiments. (B) The relative mRNA expression
of GAS6 in CLL B-cells on D0, compared with CpG/CD40L/c-stimulated
cells on D7. The data were calculated according to the relative 2–∆CT
method. The values on D7 were compared with those on D0, and the
statistical significance was calculated in a Wilcoxon test: *p<0.05. ns,
not significant.
Several studies have assessed the features of various B-cell sub-
populations after different types of in vitro stimulation. The CD40
system induces a small proportion of naive B-cells to differenti-
ate into IgM-secreting cells (few of which go on to produce IgG
and IgA) (20, 21, 52). Under the same stimulation conditions,
many CD27+ memory B-cells differentiate into predominantly
IgG-secreting ASCs (8, 18, 20, 21, 52). Bernasconi et al. (8) reported
that switched and unswitched memory B-cells respond differently
to CpG and to CD40L. The researchers showed that in contrast
to switched CD27+ memory B-cells, IgM+CD27+ memory B-
cells respond efficiently to CpG oligodeoxynucleotide but not to
CD40L (8). Indeed, the IgM+IgD+CD27+ subpopulation iso-
lated from patients with hyper-IgM syndrome type I was found to
secrete moderate levels of IgM in responses to CD40L stimulation
in the presence of IL-4 or IL-10 (14, 53). However, our previ-
ous work has shown similar results, with low IgM levels when
CLL B-cells are cultured in CD40 system (54). When triggered
by CpG in vitro, memory B-cell differentiation usually gives rise
to Ig-switched CD20− ASCs (16, 17). However, Geffroy-Luseau
et al. (18) reported the generation of CD20+ ASCs from mem-
ory B-cells and suggested that CpG preferentially stimulates a
subpopulation of IgM+ memory B-cells. Our data are similar
to those of Geffroy-Luseau et al (18) and show that CpG acti-
vation induces CLL B-cells to differentiate into IgM-producing
CD20+ ASCs. Moreover, IgM+IgD+CD27+ B-cells differentiate
into ASCs in a CpG-based stimulation system and produce IgM
and small amounts of IgG (19); in contrast, naïve B-cells do not
generate plasma cells (19). Human blood naive CD27− B-cells
do not express TLRs and require stimulation through their B-
cell receptor (BCR) to express TLR9 and become responsive to
CpG stimulation (55). When combined with BCR ligation and
CD40L stimulation, CpG induces the differentiation of naïve B
cells into ASCs that produce predominantly IgG but also some
IgM and IgA (55). Activation with CpG (in the presence or
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FIGURE 5 | Ig expression and secretion by CpG/CD40L/c-stimulated
cells. (A) CLL B-cells (on D0) and CpG/CD40L/c-stimulated cells (on D7) were
labeled before and after permeabilization with FITC-conjugated anti-human
IgM mAbs or isotype-control mAbs. Cytometry plots are representative of
four experiments. S, Surface, Cy, cytoplasmic. The bar histograms show the
relative fluorescence intensity (RFI) of surface and cytoplasmic IgM. The RFI
was calculated as the ratio between the mean fluorescence intensity (MFI) of
cells labeled with a specific antibody and the MFI of cells labeled with a
matched isotype control. Data are quoted as the mean±SEM of four
experiments. (B) Culture supernatants were harvested on D4 and D7. IgM
secretion was assessed with an ELISA. The results are quoted as the
mean±SEM (in micrograms per 106 cells) from three mutated CLL samples
and three unmutated CLL samples. (C) Culture supernatants were harvested
on D7. Secreted IgG and IgA levels were assessed with an ELISA. The red and
green point correspond to CLL samples #4 and #10, respectively. (D) The
relative expression of AICDA in CLL B-cells on D0, compared with
CpG/CD40L/c-stimulated cells on D7. The data were calculated according to
the relative 2–∆CT method. (E) The transcriptional expression of IGHG1 and
IGHA1 in CLL B-cells on D0, compared with CpG/CD40L/c-stimulated cells on
D7. Quantitative real-time PCR analysis was performed on total RNA extracted
from cells at D0 and D7. IGHG1 and IGHA1 mRNA expression are upregulated
in cells in which IgG and IgA class-switch recombination occurred [the red
(CLL#4) and green (CLL#10) points].The statistical significance was calculated
in a paired t -test: *p<0.05.
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FIGURE 6 | GeneScan analysis of IgH and IgL gene rearrangements
shows a monoclonal pattern at D0 and D7. Fragments are aligned by size
(indicated above and at the bottom of each panel). Left panels show a peak
in the IgH framework 3 (FR3)-specific size range for D0 CLL B-cells (upper
panel), D7 untreated-cells (Medium, middle panel), and D7 CpG/CD40L/
c-stimulated cells (lower panel), indicating a monoclonal rearrangement.
Right panels show a peak in the IgL-specific size range for D0 CLL B-cells,
D7 untreated-cells (medium), and D7 CpG/CD40L/c-stimulated cells,
indicating a monoclonal rearrangement. The data presented are for CLL
samples #4 and #10, in which isotype-switching was detected. The data are
representative of six experiments (CLL samples #3, #4, #6, #9, #10,
and #12)
absence of CD40L) triggers peripheral blood CD27+ memory
B cells to produce primarily IgG but also IgM and IgA (16,
17). CLL B-cells were shown to differentiate into predominantly
IgM-producing ASCs when stimulated with polyclonal B-cell acti-
vators (56, 57). Hence, CLL B-cells can differentiate into ASCs
that secreted IgM when stimulated with CpG alone (29) and in
the CpG/CD40L culture system (as shown in the present study).
These data indicate that CLL B-cells originate from a B-cell com-
partment that differentiates into predominantly IgM-producing
ASCs. However, in our experiments, only unmutated CLL B-cells
underwent CSR and produced IgA and IgG. The IgMs produced
by these cells were poly/autoreactive – indicating that the B-
cell compartment can undergo CSR occasionally and generate
poly/autoreactive antibodies. However, both SHM and CSR are
by no means restricted to germinal center sites, and can occur
ectopically. Human IgM memory B-cells do not originate from
the germinal center (9, 11, 12); they carry immunoglobulins with
low-frequency SHM, produce IgM (but also some IgG and IgA,
after in vitro differentiation) and are considered to be the main
source of “natural” antibodies in the body (9, 12). Moreover,
human IgM memory B-cells share several functions and pheno-
typic characteristics with mouse B-1a and marginal zone B-cells (9,
12). In view of these findings, we hypothesize that both unmutated
and mutated CLL B-cells are derived from IgM memory B-cells.
IgM memory B-cells initially exhibit a “natural,” quasi-germinal
IgHV repertoire, and then increase their specificity by undergo-
ing SHM upon antigen encounter and recruitment in the immune
response (9, 12, 13). Thus, the differences in mutational status
between CLL cells would be unsurprising if (i) unmutated CLL
B-cells are derived from less “antigen-experienced” IgM mem-
ory B-cells with little or no SHM [accounting for around 10%
of IgM memory B-cells (9, 13)], and (ii) mutated CLL B-cells are
derived from well“antigen-experienced”IgM memory B-cells with
a high SHM frequency. It is noteworthy that human IgM mem-
ory B-cells have a heterogeneous phenotype and include both a
CD5+CD27+ subpopulation (6) and a mutated CD27− subpop-
ulation (58). Taken as whole, our observations suggest that IgM
memory B-cells might well be the normal counterpart of CLL
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FIGURE 7 | Poly/autoreactivity of secreted IgM, as evaluated by
immunofluorescence staining of HEp-2 cells. Day 7 supernatants from
six experiments (three mutated CLL samples and three unmutated CLL
samples) were tested for reactivity with HEp-2 cells. Serum from
scleroderma was used as a positive control for autoreactivity. Indirect
immunofluorescence analysis showed that the IgM secreted into the
culture supernatant by ASCs having differentiated from unmutated CLL
B-cells were able to bind to autoantigens in HEp-2 cells. Magnification:
×200.
B-cells. However, validation of this hypothesis will require further
research.
Lastly, our data may help to improve treatment strategies for
CLL. As we and others have shown, CpG treatment of CLL B-
cells induces the upregulation of CD20 expression (59). CD20 is
the target of rituximab and other antibody-based therapies under
development (60). It is assumed that CD20 expression is low in
CLL cells. This weak CD20 expression may be responsible for the
lack of response to anti-CD20 therapy observed in certain patients.
Increasing CD20 expression on the surface of CLL cells might
increase the sensitivity of these cells to the pro-apoptotic effects
of anti-CD20 antibodies. Furthermore, it has been suggested that
differentiation therapy could be a promising way of treating CLL
(29). Moreover, rituximab has been shown to specifically deplete
autoreactive CD20+ plasma cells in a mouse model of inflamma-
tory arthritis (35). We speculate that the use of CpG/CD40L to
induce the differentiation of CLL B-cells might improve outcomes
in the treatment of CLL.
AUTHOR CONTRIBUTIONS
Hussein Ghamlouch, Brigitte Gubler, and Jean-Pierre Marol-
leau designed the study; Hussein Ghamlouch, Hakim Ouled-
Haddou, Aude Guyart, Aline Regnier, Vincent Fuentes, Jean-
François Claisse, Stéphanie Trudel performed experiments
and analyzed results; Jean-Pierre Marolleau, Brigitte Gubler,
Stéphanie Trudel, and Bruno Royer supervised the study; Hussein
Ghamlouch, Brigitte Gubler, and Jean-Pierre Marolleau wrote the
manuscript.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Paulo Marcelo (ICAP, flow
cytometry facility, UPJV, UFR Santé, Amiens, France). We would
like to thank Dr. Hakim Houchi (GRAP, INSERM ERI24, Amiens,
France) for his assistance with qRT-PCR experiments and the staff
of the Hematology Department for their assistance with MGG
staining. We also thank the Centre Hospitalier Régional Universi-
taire d’Amiens, the Conseil Régional de Picardie and the French
National Institute of Health and Medical Research (INSERM) for
their financial support.
SUPPLEMENTARY MATERIALS




1. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to
treatment of chronic lymphocytic leukaemia. Nature Rev (2010) 10(1):37–50.
doi:10.1038/nrc2764
2. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia:
cautionary notes and additional considerations and possibilities. Blood (2011)
117(6):1781–91. doi:10.1182/blood-2010-07-155663
3. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene
expression profiling of B cell chronic lymphocytic leukemia reveals a homoge-
neous phenotype related to memory B cells. J Exp Med (2001) 194(11):1625–38.
doi:10.1084/jem.194.11.1625
4. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Rela-
tion of gene expression phenotype to immunoglobulin mutation genotype
in B cell chronic lymphocytic leukemia. J Exp Med (2001) 194(11):1639–47.
doi:10.1084/jem.194.11.1639
5. Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identification of functional
human splenic memory B cells by expression of CD148 and CD27. J Exp Med
(1998) 188(9):1691–703. doi:10.1084/jem.188.9.1691
6. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, et al. Cellular
origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med (2012)
209(12):2183–98. doi:10.1084/jem.20120833
7. Schmidlin H, Diehl SA, Blom B. New insights into the regulation of human B-
cell differentiation. Trends Immunol (2009) 30(6):277–85. doi:10.1016/j.it.2009.
03.008
8. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological mem-
ory by polyclonal activation of human memory B cells. Science (2002)
298(5601):2199–202. doi:10.1126/science.1076071
9. Reynaud CA, Descatoire M, Dogan I, Huetz F, Weller S, Weill JC. IgM mem-
ory B cells: a mouse/human paradox. Cell Mol Life Sci (2012) 69(10):1625–34.
doi:10.1007/s00018-012-0971-z
10. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ periph-
eral blood B cells expressing the CD27 cell surface antigen carry somatically

























































Ghamlouch et al. CpG and CLL B-cell differentiation
mutated variable region genes: CD27 as a general marker for somatically mutated
(memory) B cells. J Exp Med (1998) 188(9):1679–89. doi:10.1084/jem.188.9.
1679
11. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human
blood IgM“memory”B cells are circulating splenic marginal zone B cells harbor-
ing a prediversified immunoglobulin repertoire. Blood (2004) 104(12):3647–54.
doi:10.1182/blood-2004-01-0346
12. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we
need IgM memory B cells? Immunol Lett (2013) 152(2):114–20. doi:10.1016/j.
imlet.2013.04.007
13. Weller S, Mamani-Matsuda M, Picard C, Cordier C, Lecoeuche D, Gauthier F,
et al. Somatic diversification in the absence of antigen-driven responses is the
hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants. J Exp Med (2008)
205(6):1331–42. doi:10.1084/jem.20071555
14. Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, et al.
Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM
syndrome. J Clin Invest (1998) 102(4):853–60. doi:10.1172/JCI3409
15. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev
Immunol (2002) 20:709–60. doi:10.1146/annurev.immunol.20.100301.064842
16. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, Zheng B, et al. CpG DNA
activation and plasma-cell differentiation of CD27− naive human B cells. Blood
(2007) 109(4):1611–9. doi:10.1182/blood-2006-03-008441
17. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, et al. An in vitro
model of differentiation of memory B cells into plasmablasts and plasma cells
including detailed phenotypic and molecular characterization. Blood (2009)
114(25):5173–81. doi:10.1182/blood-2009-07-235960
18. Geffroy-Luseau A, Chiron D, Descamps G, Jego G, Amiot M, Pellat-Deceunynck
C. TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells
from CD27+ memory B-cells. Front Immunol (2011) 2:83. doi:10.3389/fimmu.
2011.00083
19. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, Auriti C, et al. CpG
drives human transitional B cells to terminal differentiation and production of
natural antibodies. J Immunol (2008) 180(2):800–8. doi:10.4049/jimmunol.180.
2.800
20. Kindler V, Zubler RH. Memory, but not naive, peripheral blood B lymphocytes
differentiate into Ig-secreting cells after CD40 ligation and costimulation with
IL-4 and the differentiation factors IL-2, IL-10, and IL-3. J Immunol (1997)
159(5):2085–90.
21. Arpin C, Banchereau J, Liu YJ. Memory B cells are biased towards terminal dif-
ferentiation: a strategy that may prevent repertoire freezing. J Exp Med (1997)
186(6):931–40. doi:10.1084/jem.186.6.931
22. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio
F. Expression and function of toll like receptors in chronic lymphocytic
leukaemia cells. Br J Haematol (2009) 144(4):507–16. doi:10.1111/j.1365-2141.
2008.07475.x
23. Rozkova D, Novotna L, Pytlik R, Hochova I, Kozak T, Bartunkova J, et al. Toll-
like receptors on B-CLL cells: expression and functional consequences of their
stimulation. Int J Cancer (2010) 126(5):1132–43. doi:10.1002/ijc.24832
24. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Sur-
vivin is expressed on CD40 stimulation and interfaces proliferation and apop-
tosis in B-cell chronic lymphocytic leukemia. Blood (2001) 97(9):2777–83.
doi:10.1182/blood.V97.9.2777
25. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyi J, Schmitz G,
et al. Different proliferative and survival capacity of CLL-cells in a newly estab-
lished in vitro model for pseudofollicles. Leukemia (2009) 23(11):2118–28.
doi:10.1038/leu.2009.145
26. Ghamlouch H, Ouled-Haddou H, Damaj G, Royer B, Gubler B, Marolleau
JPA. Combination of cytokines rescues highly purified leukemic CLL B-
Cells from spontaneous apoptosis in vitro. PLoS One (2013) 8(3):e60370.
doi:10.1371/journal.pone.0060370
27. Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, et al. Dichotomy
in NF-kappaB signaling and chemoresistance in immunoglobulin variable
heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Oncogene (2010) 29(36):5071–82. doi:10.1038/onc.2010.248
28. Efremov DG, Bomben R, Gobessi S, Gattei V. TLR9 signaling defines distinct
prognostic subsets in CLL. Front Biosci (2013) 18:371–86. doi:10.2741/4108
29. Gutierrez A Jr, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF. Dif-
ferentiation of chronic lymphocytic leukemia B cells into immunoglobulin
secreting cells decreases LEF-1 expression. PLoS One (2011) 6(10):e26056.
doi:10.1371/journal.pone.0026056
30. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M,
Lavender FL, et al. Design and standardization of PCR primers and proto-
cols for detection of clonal immunoglobulin and T-cell receptor gene recom-
binations in suspect lymphoproliferations: report of the BIOMED-2 Concerted
Action BMH4-CT98-3936. Leukemia (2003) 17(12):2257–317. doi:10.1038/sj.
leu.2403202
31. Giudicelli V, Brochet X, Lefranc MP. IMGT/V-QUEST: IMGT standardized
analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide
sequences. Cold Spring Harb Protoc (2011) 2011(6):695–715. doi:10.1101/pdb.
prot5634
32. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The het-
erogeneity shown by human plasma cells from tonsil, blood, and bone mar-
row reveals graded stages of increasing maturity, but local profiles of adhe-
sion molecule expression. Blood (2002) 99(6):2154–61. doi:10.1182/blood.V99.
6.2154
33. Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I. Advances in human B cell
phenotypic profiling. Front Immunol (2012) 3:302. doi:10.3389/fimmu.2012.
00302
34. Withers DR, Fiorini C, Fischer RT, Ettinger R, Lipsky PE, Grammer AC. T cell-
dependent survival of CD20+ and CD20− plasma cells in human secondary
lymphoid tissue. Blood (2007) 109(11):4856–64. doi:10.1182/blood-2006-08-
043414
35. Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived
autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl
Acad Sci U S A (2010) 107(10):4658–63. doi:10.1073/pnas.1001074107
36. Medina KL, Pongubala JM, Reddy KL, Lancki DW, Dekoter R, Kieslinger M,
et al. Assembling a gene regulatory network for specification of the B cell fate.
Dev Cell (2004) 7(4):607–17. doi:10.1016/j.devcel.2004.08.006
37. Neurath MF, Max EE, Strober W. Pax5 (BSAP) regulates the murine
immunoglobulin 3’ alpha enhancer by suppressing binding of NF-alpha P, a
protein that controls heavy chain transcription. Proc Natl Acad Sci U S A (1995)
92(12):5336–40. doi:10.1073/pnas.92.12.5336
38. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malig-
nancy. Nat Rev Immunol (2008) 8(1):22–33. doi:10.1038/nri2217
39. Ochiai K, Katoh Y, Ikura T, Hoshikawa Y, Noda T, Karasuyama H, et al. Plasma-
cytic transcription factor Blimp-1 is repressed by Bach2 in B cells. J Biol Chem
(2006) 281(50):38226–34. doi:10.1074/jbc.M607592200
40. Turner CA Jr., Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing
protein that can drive the maturation of B lymphocytes into immunoglobulin-
secreting cells. Cell (1994) 77(2):297–306. doi:10.1016/0092-8674(94)90321-2
41. Iwakoshi NN, Lee AH, Glimcher LH. The X-box binding protein-1 transcrip-
tion factor is required for plasma cell differentiation and the unfolded pro-
tein response. Immunol Rev (2003) 194:29–38. doi:10.1034/j.1600-065X.2003.
00057.x
42. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced
by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active
transcription factor. Cell (2001) 107(7):881–91. doi:10.1016/S0092-8674(01)
00611-0
43. De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, et al. Identi-
fying intercellular signaling genes expressed in malignant plasma cells by using
complementary DNA arrays. Blood (2001) 98(3):771–80. doi:10.1182/blood.
V98.3.771
44. Dirks W, Rome D, Ringel F, Jager K, MacLeod RA, Drexler HG. Expression of
the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines.
Leuk Res (1999) 23(7):643–51. doi:10.1016/S0145-2126(99)00075-2
45. Fais F, Sellars B, Ghiotto F, Yan XJ, Dono M, Allen SL, et al. Examples of in vivo
isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin
Invest (1996) 98(7):1659–66. doi:10.1172/JCI118961
46. Malisan F, Fluckiger AC, Ho S, Guret C, Banchereau J, Martinez-Valdez H.
B-chronic lymphocytic leukemias can undergo isotype switching in vivo and
can be induced to differentiate and switch in vitro. Blood (1996) 87(2):
717–24.
47. Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C, Payelle-Brogard B,
et al. Chronic lymphocytic leukemia B cells expressing AID display dissociation
between class switch recombination and somatic hypermutation. Blood (2003)
101(10):4029–32. doi:10.1182/blood-2002-10-3175

























































Ghamlouch et al. CpG and CLL B-cell differentiation
48. Palacios F, Moreno P, Morande P, Abreu C, Correa A, Porro V, et al. High expres-
sion of AID and active class switch recombination might account for a more
aggressive disease in unmutated CLL patients: link with an activated microen-
vironment in CLL disease. Blood (2010) 115(22):4488–96. doi:10.1182/blood-
2009-12-257758
49. Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, et al. Unmu-
tated and mutated chronic lymphocytic leukemias derive from self-reactive B cell
precursors despite expressing different antibody reactivity. J Clin Invest (2005)
115(6):1636–43. doi:10.1172/JCI24387
50. Lanemo Myhrinder A, Hellqvist E, Sidorova E, Soderberg A, Baxendale H, Dahle
C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells,
and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood
(2008) 111(7):3838–48. doi:10.1182/blood-2007-11-125450
51. Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, et al. Chronic lym-
phocytic leukemia cells recognize conserved epitopes associated with apoptosis
and oxidation. Mol Med (2008) 14(11–12):665–74. doi:10.2119/2008-00102.
Catera
52. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, et al. Generation of
polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of
malignant plasmablasts. Blood (2002) 100(4):1113–22.
53. Durandy A, Hivroz C, Mazerolles F, Schiff C, Bernard F, Jouanguy E, et al. Abnor-
mal CD40-mediated activation pathway in B lymphocytes from patients with
hyper-IgM syndrome and normal CD40 ligand expression. J Immunol (1997)
158(6):2576–84.
54. Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, et al.
Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B
cells into Ab-secreting cells. Immunol Cell Biol (2014). doi:10.1038/icb.2014.37
55. Le Gallou S, Caron G, Delaloy C, Rossille D, Tarte K, Fest T. IL-2 require-
ment for human plasma cell generation: coupling differentiation and prolifer-
ation by enhancing MAPK-ERK signaling. J Immunol (2012) 189(1):161–73.
doi:10.4049/jimmunol.1200301
56. van Kooten C, Rensink I,Aarden L, van Oers R. Differentiation of purified malig-
nant B cells induced by PMA or by activated normal T cells. Leukemia (1993)
7(10):1576–84.
57. Tangye SG, Weston KM, Raison RL. Phorbol ester activates CD5+ leukaemic B
cells via a T cell-independent mechanism. Immunol Cell Biol (1995) 73(1):44–51.
doi:10.1038/icb.1995.7
58. Weston-Bell N, Townsend M, Di Genova G, Forconi F, Sahota SS. Defining
origins of malignant B cells: a new circulating normal human IgM(+)D(+) B-
cell subset lacking CD27 expression and displaying somatically mutated IGHV
genes as a relevant memory population. Leukemia (2009) 23(11):2075–80.
doi:10.1038/leu.2009.178
59. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E,
et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynu-
cleotides. Clin Cancer Res (2005) 11(4):1490–9. doi:10.1158/1078-0432.CCR-
04-1890
60. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical
application of monoclonal antibodies in chronic lymphocytic leukemia. Blood
(2010) 116(19):3705–14. doi:10.1182/blood-2010-04-001230
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 21 February 2014; accepted: 03 June 2014; published online: 16 June 2014.
Citation: Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse
J-F, Fuentes V, Royer B, Marolleau J-P and Gubler B (2014) TLR9 ligand (CpG
oligodeoxynucleotide) induces CLL B-cells to differentiate into CD20+ antibody-
secreting cells. Front. Immunol. 5:292. doi: 10.3389/fimmu.2014.00292
This article was submitted to B Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Ghamlouch, Ouled-Haddou, Guyart , Regnier , Trudel, Claisse,
Fuentes, Royer, Marolleau and Gubler . This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org June 2014 | Volume 5 | Article 292 | 13
